PDSB Stock Forecast & Price Target

PDS Biotechnology is viewed positively because the Nant-led PIPE, up to $22.55M with an initial $11.55M closing and a contingent $11M tranche tied to FDA submission, materially eases the $5.6M cash position reported at 2Q26 and lowers funding risk. The company’s refocus on PDS0301, while discontinuing internal funding for the costly Phase 3 VERSATILE-003 study of PDS0101, concentrates scarce capital on a program with encouraging early mCRC data, including 7/9 responses at six months in the initial study and 22-patient survival that remained not yet estimable after more than 34 months. Further support comes from the ~36% workforce reduction, which should reduce R&D and G&A spending, while the lower discount rate to 18% reflects an improved financial risk profile despite dilution and residual development risk.

PDS Biotechnology is facing a fundamentally fragile investment case because financing is the key gating factor, with management indicating about $15M is needed to fund the randomized mCRC study through interim analysis and another $15M to support operations over the same period. The company’s depressed equity value makes that funding need difficult to meet, so dilution risk remains central even as the strategic refocus has some clinical logic. A conservative valuation also reflects only a 25% probability of success for PDS0301, narrower liver-metastatic MSS/pMMR assumptions, pushed-out 2031 launch timing for PDS0101, and a higher 20% discount rate due to elevated financing risk.